AI-generated summary
In this retrospective pilot study of ten eyes from nine patients with chronic central serous chorioretinopathy, the authors report that photobiomodulation at 590 and 625 nm was associated with improved visual acuity and fluid resolution at six months. They also report no adverse events, but note that prospective controlled trials are needed to confirm efficacy and durability.
- Participants
- 9
- Who or what was studied
- Nine patients (ten eyes) with chronic central serous chorioretinopathy, each with persistent subretinal fluid for at least six months and no prior laser therapy.
- Wavelengths
- 590, 625 nm
- Limits stated in the abstract
- The study is retrospective, uses a very small sample, and has no control group, so the authors themselves call for prospective controlled trials.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on link.springer.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 625 nm
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Photobiomodulation therapy, Pilot study, Wavelength, Laser. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.